• Product NameDasatinib
• Brief DescriptionInhibitors
• Purification99.62%
• Biological ActivityDasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
• Target NameBcr-Abl inhibitor; c-Kit inhibitor; Ephrin Receptor inhibitor; Src inhibitor
• CAS No. 302962-49-8
• Calculated MW 488.01
• Formulation C22H26ClN7O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=N1)N1CCN(CCO)CC1
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors; Cytoskeletal Signaling
  Receptor:Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src
  Boling pt:
  Melting pt:275-286C
  Solubility:DMSO: 98 mg/mL (200.81 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. O'Hare T, et al. Y Res. 2005, 65(11), 4500-4505.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting